NEWARK, Calif., Jan. 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Eliseo Salinas, M.D., Executive Vice President and Head of Research and Development, will provide an update on the StemCells, Inc. development programs and translational work being done with the Company's proprietary HuCNS-SC® human neural stem cells, at the 2014 Alliance for Regenerative Medicine (ARM) State of the Industry Briefing. Dr. Salinas will discuss the Company's plans for completing ongoing safety studies in spinal cord injury and age related macular degeneration (AMD) in the first and second quarters of 2014 respectively, as well as the planned initiation of controlled Phase II efficacy studies in both indications in 2014. The new trials are being designed as definitive Proof of Concept studies with hard clinical outcomes, which should enable the Company to initiate pivotal Phase III studies, assuming that the results are positive. Dr. Salinas is scheduled to speak on January 13th, from 8:00 to 10:00 a.m., at the conference, which is being held at the Parc 55 Wyndham Hotel in San Francisco, CA.
StemCells, Inc. To Discuss Plans For Advancing Clinical Studies In Spinal Cord Injury And Age Related Macular Regeneration
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts